CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 14 enrolled
Drug / intervention
Ibrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03702725
NCT03702725Phase 1Completed
CompareCT.gov

A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma

Alliance Foundation Trials, LLC.·interventional·Posted Oct 11, 2018·Updated Jan 6, 2026

In Brief

A Phase 1 clinical trial evaluating Ibrutinib, Lenalidomide, and 1 other intervention for Refractory Multiple Myeloma and 2 related conditions. Completed, enrolled 14 participants across 5 sites.

Detailed Summary

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma
CountriesUnited States
CollaboratorsPharmacyclics LLC.

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedOct 11, 2018
Enrollment StartAug 29, 2019
Primary CompletionSep 27, 2024
Study CompletionOct 4, 2024
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 7.7 years ago

Interventions

Ibrutinibdrug

Ibrutinib administered on every day of each 28 day cycle. Dosage depends on timing of patient enrollment and dosage tolerance by patients already enrolled.

Lenalidomidedrug

Lenalidomide administered on days 1-21 of each 28 day cycle. Dosage depends on findings from Dose Escalation phase.

Dexamethasonedrug

Dexamethasone administered on days 1, 8, 15, and 22 of every 28 day cycle. Dosage depends on findings from Dose Escalation phase.